ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 117 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $442 | -28.0% | 22,013 | +1.1% | 0.00% | 0.0% |
| Q2 2023 | $614 | +48.7% | 21,763 | -9.3% | 0.00% | 0.0% |
| Q1 2023 | $413 | -39.2% | 23,994 | -28.8% | 0.00% | 0.0% |
| Q4 2022 | $679 | -99.9% | 33,698 | +0.2% | 0.00% | 0.0% |
| Q3 2022 | $729,000 | -78.2% | 33,641 | -71.8% | 0.00% | -75.0% |
| Q2 2022 | $3,350,000 | -39.1% | 119,201 | -0.1% | 0.00% | -33.3% |
| Q1 2022 | $5,503,000 | -44.2% | 119,277 | +1.6% | 0.01% | -40.0% |
| Q4 2021 | $9,865,000 | +515.0% | 117,352 | +387.7% | 0.01% | +400.0% |
| Q3 2021 | $1,604,000 | +3.1% | 24,063 | -17.7% | 0.00% | 0.0% |
| Q2 2021 | $1,556,000 | +32.8% | 29,247 | +8.3% | 0.00% | +100.0% |
| Q1 2021 | $1,172,000 | -10.1% | 27,000 | +7.6% | 0.00% | 0.0% |
| Q4 2020 | $1,304,000 | +319.3% | 25,100 | +164.2% | 0.00% | – |
| Q3 2020 | $311,000 | -31.8% | 9,500 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $456,000 | – | 9,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |